Chimerix (NASDAQ: CMRX) and Array BioPharma (NASDAQ:ARRY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Chimerix and Array BioPharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chimerix -1,440.67% -26.00% -25.10%
Array BioPharma -89.30% -158.70% -38.54%

Analyst Recommendations

This is a summary of recent ratings for Chimerix and Array BioPharma, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chimerix 0 2 0 0 2.00
Array BioPharma 0 1 7 0 2.88

Chimerix presently has a consensus target price of $6.50, suggesting a potential upside of 49.77%. Array BioPharma has a consensus target price of $14.13, suggesting a potential upside of 25.56%. Given Chimerix’s higher probable upside, equities analysts clearly believe Chimerix is more favorable than Array BioPharma.

Volatility and Risk

Chimerix has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Array BioPharma has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500.

Valuation and Earnings

This table compares Chimerix and Array BioPharma’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chimerix $5.70 million 35.88 -$76.39 million ($1.43) -3.03
Array BioPharma $150.85 million 14.69 -$116.81 million ($0.74) -15.20

Chimerix has higher earnings, but lower revenue than Array BioPharma. Array BioPharma is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

70.4% of Chimerix shares are owned by institutional investors. Comparatively, 98.2% of Array BioPharma shares are owned by institutional investors. 10.5% of Chimerix shares are owned by company insiders. Comparatively, 3.2% of Array BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Array BioPharma beats Chimerix on 7 of the 13 factors compared between the two stocks.

Chimerix Company Profile

Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.

Array BioPharma Company Profile

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.